Abbonarsi

Does the public know when a scientific controversy is over? Public perceptions of hydroxychloroquine in France between April 2020 and June 2021 - 27/09/22

Doi : 10.1016/j.therap.2022.01.008 
Émilien Schultz a, b, , Laëtitia Atlani-Duault a, c, d, e, Patrick Peretti-Watel f, g, Jeremy K. Ward f, h
a Université de Paris, IRD, Inserm, CEPED (UMR 196), 75006 Paris, France 
b Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Equipe CANBIOS Labellisée Ligue Contre le Cancer, 13005 Marseille, France 
c Institut COVID-19 Add Memoriam, université de Paris, 75006 Paris, France 
d WHO Collaborative Center for Research on Health and Humanitarian Policies and Practices, IRD, université de Paris, 75006 Paris, France 
e Columbia University, Mailman School of Public Health, New York, NY, USA 
f VITROME, Aix-Marseille université, IRD, AP–HM, SSA, 13005 Marseille, France 
g Observatoire régional de la santé PACA (ORS Paca), Aix-Marseille université, 13385 Marseille, France 
h CERMES3, Inserm, CNRS, EHESS, université de Paris, 94801 Villejuif, France 

Corresponding author. CEPED, 45, rue des Saints-Pères, 75006 Paris, France.CEPED45, rue des Saints-PèresParis75006France

Summary

Objectives

In the early stages of the coronavirus disease 2019 (COVID-19) pandemic, chloroquine and its derivatives such as hydroxychloroquine (HCQ) were widely commented upon both within the scientific community and in the media. This paper explores the different factors that influenced public perceptions in France of the efficacy of HCQ as well as their evolution between April 2020 and June 2021.

Methods

This article draws on 5 surveys conducted among representative samples of the French population (projects COCONEL and TRACTRUST; quota method, n=1006; 1004; 2006; 1014 and 1005). We asked questions on the effectiveness of chloroquine against COVID-19. We also collected sociodemographic variables and attitudes toward politics and science.

Results

Between April and June 2021, the proportion of respondents who believed in the efficacy of HCQ decreased rapidly from 35% to 14%. The proportion of respondents who believed that HCQ is ineffective rose gradually from 6% to 21%. After adjusting for the temporal effect, the logistic regression showed a very strong association between political orientation and the belief in the efficacy of HCQ. Respondents who felt closest to the more radical parties (far-right and far-left) were more likely to believe in the efficacy of HCQ than those who felt closest to the political center (O.R. 2.48 [1.95–3.15] and 1.87 [1.44–2.43]). The role of trust in the government and in science and of the degree of political engagement were investigated in the two waves conducted after the scientific consensus was established during the summer of 2020. High levels of trust in the government and in science and of politicization are associated with belief of HCQ proven inefficacy. Across the whole period, a majority of respondents were uncertain. Even in 2021, 41.5% stated that the data were insufficient to decide whether or not HCQ is effective and 25.2% stating that they did not know.

Conclusion

Because media coverage of scientific controversies is higher in times of uncertainty than after these controversies have died down, the publicization of therapeutic promises can have lasting consequences on attitudes towards science and medicine.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : COVID-19, Chloroquine, Surveys, Public attitude, Sociology, Hydroxychloroquine


Mappa


© 2022  The Author(s). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 77 - N° 5

P. 591-602 - settembre 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Pharmacologie du cannabidiol : points de vigilance, conséquences et risques chez l’homme
  • Joëlle Micallef, Anne Batisse, Bruno Revol
| Articolo seguente Articolo seguente
  • Suivi thérapeutique pharmacologique de la cyamémazine : comment interpréter une concentration ? Une revue de la littérature
  • Hugo Alarcan, David Schnell, Stéphane Rouleau, Anissa Chachia, Franck Saint-Marcoux, Olivier Mathieu, Sylvain Couderc

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.